Stonepine Capital Management LLC Acquires New Position in Savara Inc. $SVRA

Stonepine Capital Management LLC acquired a new stake in shares of Savara Inc. (NASDAQ:SVRA) in the first quarter, HoldingsChannel reports. The institutional investor acquired 29,079 shares of the company’s stock, valued at approximately $81,000.

Other hedge funds also recently made changes to their positions in the company. XTX Topco Ltd bought a new position in Savara in the 4th quarter worth approximately $34,000. Ameriprise Financial Inc. bought a new position in Savara in the 4th quarter worth approximately $37,000. Hsbc Holdings PLC bought a new position in Savara in the 4th quarter worth approximately $48,000. Jump Financial LLC bought a new position in Savara in the 4th quarter worth approximately $64,000. Finally, Brooklyn Investment Group bought a new position in Savara in the 1st quarter worth approximately $65,000. 87.93% of the stock is currently owned by institutional investors.

Savara Stock Up 3.6%

NASDAQ SVRA opened at $3.16 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 11.08 and a current ratio of 11.08. The company has a market capitalization of $546.17 million, a P/E ratio of -6.32 and a beta of 0.40. Savara Inc. has a one year low of $1.89 and a one year high of $4.70. The stock has a 50 day moving average price of $2.47 and a 200-day moving average price of $2.67.

Savara (NASDAQ:SVRA) last posted its earnings results on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). As a group, equities analysts predict that Savara Inc. will post -0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SVRA has been the subject of several recent analyst reports. Evercore ISI dropped their price target on Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a research note on Wednesday, May 28th. Guggenheim restated a “buy” rating and issued a $8.00 price target (down from $9.00) on shares of Savara in a research note on Wednesday, May 28th. HC Wainwright upgraded Savara from a “neutral” rating to a “buy” rating and upped their price target for the stock from $2.00 to $5.00 in a research note on Friday, August 15th. Wells Fargo & Company dropped their price target on Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Wednesday, May 28th. Finally, Oppenheimer upped their price target on Savara from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, August 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Savara has an average rating of “Moderate Buy” and an average target price of $6.17.

Insider Activity at Savara

In other news, Director Richard J. Hawkins bought 48,225 shares of the stock in a transaction dated Friday, June 20th. The stock was purchased at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the transaction, the director owned 115,466 shares of the company’s stock, valued at $235,550.64. The trade was a 71.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 5.33% of the company’s stock.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.